MedPath

Role of Biomarkers in Patients Undergoing Dialysis Treatment

Completed
Conditions
Volemia in Dialysis Patients
Interventions
Device: bioelectrical impedance measurement and biomarker measurement
Registration Number
NCT02962635
Lead Sponsor
University of Zurich
Brief Summary

A precise volume status assessment is critical to improve outcome of patients on dialysis. Yet, accurate assessment of fluid status remains a challenge. Currently, this is performed by clinical evaluation and regular weight measurements before and after dialysis, which is not always accurate. Moreover, bioimpedance technology is used in some centers for quantitative assessment of total body water. This approach has been validated for the assessment of volume status in dialysis patients, but requires the acquisition of specific tools and is time consuming. So far, no biomarker has been validated to quantify volume status in dialysis patients. Application of biomarkers might contribute to a better dialysis prescription and therefore to outcome improvement in dialysis. The investigators aim to investigate the role of a novel biomarkers (sCD146) to assess volume status in dialysis patients

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Age > 18 years old
  • Patient on dialysis since > 1 month
  • Voluntarily signed informed consent
Exclusion Criteria
  • Pregnant or breastfeeding women and women who plan to get pregnant during study
  • Incapability of following the study protocol
  • Acute illness
  • Hospitalizations in the last week before inclusion
  • Cardiac pacemakers or defibrillators
  • Limb amputation or other factors precluding a reliable bioimpedance measurement (unreliable bioimpedance measurement)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Hemodialysis patientsbioelectrical impedance measurement and biomarker measurementA total of 30 patients - measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker
Peritoneal dialysis patientsbioelectrical impedance measurement and biomarker measurementA total of 15 patients - measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker
Primary Outcome Measures
NameTimeMethod
Correlation of sCD146 level with overhydration assessed by bioimpedance technology3 weeks to 3 months

For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months

Secondary Outcome Measures
NameTimeMethod
Correlation of sCD146 level and clinical evaluation of volume status3 weeks to 3 months

For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months

Correlation of sCD146 level and hospitalizations as assessed prospectively in 6 months follow-up6 months
Correlation of sCD146 level and shunt complications as assessed prospectively in 6 months follow-up6 months
Correlation of sCD146 level measured after dialysis and ultrafiltration rate3 weeks

for hemodialysis patients measurements will be concluded within 3 weeks

Correlation of sCD146 level and level of NT-proBNP3 weeks to 3 months

For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months

Correlation of sCD146 level and mortality as assessed prospectively in 6 months follow-up6 months
Correlation of sCD146 level and cardiovascular complications as assessed prospectively in 6 months follow-up6 months

Trial Locations

Locations (1)

University Hospital Zürich

🇨🇭

Zurich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath